PP_1170x120_10-25-21

mylan

Mylan names GSK veteran as global OTC leader

Mylan names GSK veteran as global OTC leader

HERTFORDSHIRE, England, and PITTSBURGH — Mylan N.V. has tabbed GlaxoSmithKline Consumer Healthcare veteran Ranjan Ray Chaudhuri to serve as global commercial lead of Mylan’s over-the-counter business. Chaudhuri will report to Rajiv Malik, president of Mylan. “The opportunity to build upon Mylan’s one-of-a-kind global platform and contribute to the organization’s ongoing evolution is tremendously exciting to

Mylan takes hostile bid to Perrigo stockholders

Mylan takes hostile bid to Perrigo stockholders

HERTFORDSHIRE, England — As promised, Mylan N.V. has proceeded to make formal bid to acquire Perrigo Co. plc in a deal valued at approximately $27 billion. Mylan said Monday that under the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share. That would translate to a

Yasmin generic released by Mylan

Yasmin generic released by Mylan

PITTSBURGH — Mylan N.V. has announced the U.S. launch of drospirenone and ethinyl estradiol tablets (3 mg/0.03 mg), an oral contraceptive. Mylan said Tuesday that the product, a generic version of Yasmin tablets from Bayer, is available immediately and represents its 13th oral contraceptive launch in the United States. Mylan’s partner Famy Care Ltd. received

Teva to buy Allergan Generics for $40.5 billion

Teva to buy Allergan Generics for $40.5 billion

JERUSALEM — Teva Pharmaceutical Industries Ltd. plans to buy Allergan’s generic drug business for about $40.5 billion and, with the deal, has withdrawn its proposal to acquire Mylan N.V. for approximately $40 billion. Teva said Monday that Dublin, Ireland-based Allergan will receive $33.75 billion in cash and $6.75 billion in shares of Teva. The agreement

Mylan, Teva roll out generic versions of Intuniv

Mylan, Teva roll out generic versions of Intuniv

NEW YORK — Mylan N.V. and Teva Pharmaceutical Industries Ltd. have released guanfacine extended-release tablets, a nonstimulant medication for attention deficit hyperactivity disorder (ADHD), in the United States. The pharmaceutical companies said Tuesday that their products, available in strengths of 1 mg, 2 mg, 3 mg and 4 mg, are generic equivalents of Intuniv from

Mylan raises bid, Perrigo again rejects

NEW YORK — Mylan N.V. has upped its offer to acquire Perrigo Co. plc but received the same response: no. On Wednesday, Mylan announced an increased bid in which Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share, a deal valued at more than $35 billion. But

Mylan says no to Teva’s acquisition bid

POTTERS BAR, England — Mylan N.V. has rejected an unsolicited bid to be acquired by Teva Pharmaceutical Industries Ltd. in a cash-and-stock deal valued at more than $40 billion. Mylan said Monday that its board of directors unanimously voted against Teva’s offer, which was announced on April 21. Mylan stated that after a comprehensive review

Perrigo nixes Mylan’s takeover bid

DUBLIN, Ireland — The board of directors of Perrigo Co. plc has unanimously rejected Mylan N.V.’s unsolicited bid to buy the company. Perrigo said late Tuesday that Mylan’s $205-per-share offer earlier this month, a deal estimated at about $29 billion, undervalues the company and its growth prospects. “The board believes the proposal substantially undervalues Perrigo

Teva offers to buy Mylan in $40 billion deal

JERUSALEM — Teva Pharmaceutical Industries Ltd. has made a bid to acquire Mylan N.V. in a cash-and-stock deal valued at about $40 billion. In announcing its offer Tuesday, Teva said its proposal is a more attractive option for shareholders of Mylan, which nearly two weeks ago made an unsolicited bid to buy Perrigo Co. plc

Mylan makes bid to acquire Perrigo for $29 billion

Mylan makes bid to acquire Perrigo for $29 billion

POTTERS BAR, England — Mylan N.V. has made an unsolicited bid to acquire Dublin, Ireland-based Perrigo Co. plc in a cash-and-stock deal valued at about $29 billion. Mylan said Wednesday that under the proposal — delivered to Perrigo chairman, president and chief executive officer Joseph Papa — Perrigo shareholders would receive $205 in cash and

Mylan releases Generess Fe generic in U.S.

POTTERS BAR, England, and PITTSBURGH — Mylan N.V. has launched norethindrone and ethinyl estradiol chewable tablets (0.8 mg/0.025 mg) and ferrous fumarate chewable tablets (75 mg) in the United States. Mylan said Tuesday that its product is the first generic version of Warner Chilcott’s Generess Fe tablets, an oral contraceptive, and entitles it to 180